With the GDPR recently coming into effect, U.S. policymakers and industry players have found opportunities to critic the GDPR on the grounds that it will somehow harm health care. The U.S. secretary of commerce recently insisted without evidence that European law will stop lifesaving drugs from coming to market. Others with a stake in the industry have suggested that the GDPR’s limits on data sharing will actually hurt people seeking medical care. The attack on privacy laws for health information motivated me to draft an opinion piece for STAT.

// Read the full essay at STAT First Opinion.